Gland Pharma has signed a strategic Manufacturing and Supply Agreement with a leading global pharmaceutical company for technology transfer, manufacturing and supply of sterile injectable products. The agreement covers 55 SKUs across three sites, with annualised revenue potential of $90-100 million upon commercialisation. Revenue generation is expected to begin in 2029.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.